Femasys (NASDAQ:FEMY) Cut to “Sell” at Zacks Investment Research

Femasys (NASDAQ:FEMYGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “Femasys Inc.is a biomedical company focused on transforming women’s healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company’s lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA. “

FEMY has been the topic of several other research reports. Chardan Capital reduced their price target on shares of Femasys from $25.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, March 25th. HC Wainwright initiated coverage on shares of Femasys in a research report on Thursday, March 24th. They issued a “buy” rating and a $8.00 price target on the stock.

Shares of Femasys stock traded down $0.34 on Tuesday, hitting $1.45. 131,376 shares of the company traded hands, compared to its average volume of 162,793. The stock has a market capitalization of $17.13 million and a P/E ratio of -1.41. Femasys has a 52 week low of $1.40 and a 52 week high of $13.75. The business has a 50-day simple moving average of $1.81 and a 200 day simple moving average of $3.11.

Femasys (NASDAQ:FEMYGet Rating) last released its quarterly earnings data on Thursday, March 24th. The company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $0.25 million for the quarter. Femasys had a negative net margin of 733.65% and a negative return on equity of 31.42%. As a group, research analysts anticipate that Femasys will post -1.01 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Clear Creek Financial Management LLC boosted its stake in Femasys by 190.2% during the fourth quarter. Clear Creek Financial Management LLC now owns 68,276 shares of the company’s stock worth $266,000 after buying an additional 44,752 shares during the period. BlackRock Inc. purchased a new position in Femasys during the third quarter worth $40,000. Baird Financial Group Inc. purchased a new position in Femasys during the fourth quarter worth $57,000. Virtu Financial LLC purchased a new position in Femasys during the fourth quarter worth $50,000. Finally, Cetera Advisor Networks LLC purchased a new position in Femasys during the first quarter worth $27,000. 4.54% of the stock is owned by institutional investors.

About Femasys (Get Rating)

Femasys Inc, a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.

Further Reading

Get a free copy of the Zacks research report on Femasys (FEMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.